Search

Home > Diabetes Knowledge into Practice Podcast > Hypoglycaemia: minimising the risk among insulin-treated patients


	Podcast:		Diabetes Knowledge into Practice Podcast
	Episode:		Hypoglycaemia: minimising the risk among insulin-treated patients
	Category:		Health
	Duration:		00:16:01
	Publish Date:		2020-08-18 09:55:02
	Description:		As discussed in our previous episode, it is vital to monitor blood glucose when receiving insulin-based therapy due to the risk of hypoglycaemia. However, given the relative crudeness of insulin-based treatment, SMBG testing is not an infallible way of preventing hypogycaemia. What are the other risks, and how can we address these? Join Professor Simon Heller of the University of Sheffield for a detailed discussion of risk factors, management strategies, and how to empower patients to minimise their risk of hypoglycaemia References Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. Iqbal A, Heller SR. The role of structured education in the management of hypoglycaemia. Diabetologia. 2018;61(4):751-760. Philis-Tsimikas, A., Klonoff, D.C., Khunti, K. et al. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia 63, 698–710 (2020). Silbert R, Salcido-Montenegro A, Rodriguez-Gutierrez R, Katabi A, McCoy RG. Hypoglycemia Among Patients with Type 2 Diabetes: Epidemiology, Risk Factors, and Prevention Strategies. Curr Diab Rep. 2018;18(8):53. Published 2018 Jun 21. Yorke E, Atiase Y. Impact of structured education on glucose control and hypoglycaemia in Type-2 diabetes: a systematic review of randomized controlled trials. Ghana Med J. 2018;52(1):41-60. This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education
	Total Play:		0